emily oster glp 1 Community Focus: Dr. discusses GLP-1 drugs' impact on weight loss Dr. Emily Oster on science

Data acquisition Exendin-4: Data for the GLP1R:DNGs:exendin- complex was collected on a Titan Krios microscope operated at 300 kV (ThermoFisher Scientific equipped with a Gatan Quantum energy filter operating in Zero Loss mode with an energy slit with of 20 eV and a Gatan K2 Summit direct electron detector (Gatan)

Short duration drugs, such as propofol or dexmedetomidine should be utilized to sedate intensive care patients

Deciphering molecular interactions by proximity labeling

GLP-1 Medications: Work with natural hunger hormones Multiple complementary mechanisms Target biological causes of overeating Produce 10-22% average weight loss Much more effective than traditional options Medical Uses: FDA-Approved Indications: For Type 2 Diabetes: All GLP-1 medications originally approved for diabetes Improve blood sugar control Reduce A1C by 1-2 percentage points Lower risk of cardiovascular events For Chronic Weight Management: Semaglutide (Wegovy): Approved 2021 Tirzepatide (Zepbound): Approved 2023 Liraglutide (Saxenda): Approved 2014 Requirements for weight loss approval: BMI 30, or BMI 27 with weight-related condition (diabetes, hypertension, sleep apnea, etc.) Off-Label Use: Many doctors prescribe diabetes versions (Ozempic, Mounjaro) off-label for weight loss because: Identical medication to weight loss versions Sometimes better insurance coverage Same effectiveness regardless of indication on label This is legal and common medical practice